|
|
|
|
|
|
|
|
|
 |  |  |  | | USD | EUR | GBP | JPY | | 83.44 | 89.46 | 104.56 | 0.53 |
 |  |  |  | | AED | AUD | CHF | CAD | | 17.54 | 49.53 | 64.49 | 50.06 |
 |  |  |  | | HKD | SAR | SGD | ZAR | | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1740.00
|
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
|
|
02-05-2024
|
|
|
|
| RPG Life Sciences Limited has informed the Exchange about Link of Recording |
|
|
|
|
|
01-05-2024
|
|
|
|
| In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper publications with respect to Audited Financial Results for the quarter and year ended March 31, 2024. |
|
|
|
|
|
01-05-2024
|
|
|
|
| RPG Life Sciences Limited has informed the Exchange about Investor Presentation |
|
|
|
|
|
30-04-2024
|
|
|
|
| RPG Life Sciences Limited has informed the Exchange regarding Change in Director(s) of the company. |
|
|
|
|
|
30-04-2024
|
|
|
|
| RPG LIFE SCIENCES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent |
|
|
|
|
|
30-04-2024
|
|
|
|
| In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Tuesday, April 30, 2024, inter-alia considered and unanimously: 1. Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2024. Copy of the same is enclosed along with the Report of the Auditors thereon and a declaration stating that the said report is with unmodified opinion.2. Recommended equity dividend of Rs. 16 per share of Rs. 8/- each (200 %) for the financial year ended March 31, 2024, which will be paid to the shareholders within 30 days of declaration of the same at the ensuing Annual General Meeting.3. Approved the Audited Financial Statements of the Company, for the year ended March 31, 2024.4. Considered on recommendation of the Nomination and Remuneration Committee, appointment of Mr. Anil Matai (DIN: 03122685), as an Additional Director in the capacity of Non-Executive, Independent Director of the Company for a period of five years w.e.f. April 30, 2024, till April 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution Refer Annexure A.5. Considered on recommendation of the Nomination and Remuneration Committee, appointment of Mr. Hiten Kotak (DIN: 00191115), as an Additional Director in the capacity of Non-Executive, Independent Director of the Company for a period of five years w.e.f. April 30, 2024, till April 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution Refer Annexure B.6. Considered on recommendation of the Nomination and Remuneration Committee, appointment of Ms. Radhika Gupta (DIN: 02657595), as an Additional Director in the capacity of Non-Executive, Independent Director of the Company for a period of five years w.e.f. April 30, 2024, till April 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution Refer Annexure C. 7. Considered on recommendation of the Nomination and Remuneration Committee, appointment of Mr. Sachin Nandgaonkar (DIN: 03410739), Non-Executive, Non Independent Director as Non - Executive, Independent Director of the Company for a period of five years w.e.f. April 30, 2024, till April 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution Refer Annexure D.8. Recommended re-appointment of Mr. Bhaskar Iyer (DIN: 00480341) as Non-Executive, Independent Director of the Company, for a second term effective from October 30, 2024 till October 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution Refer Annexure E.9. Reconstituted committees of the BoardThe disclosures as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 and pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed herewith.The meeting commenced at 03:00 p.m. and concluded at 6.45 p.m. |
|
|
|
|
|
30-04-2024
|
|
|
|
| Board Meeting of the Company held on April 30, 2024, recommended equity dividend of Rs. 16 per share of Rs. 8/- each (200 %) for the financial year ended March 31, 2024, which will be paid to the shareholders within 30 days of declaration of the same at the ensuing Annual General Meeting. |
|
|
|
|
|
30-04-2024
|
|
|
|
| RPG Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024. |
|
|
|
|
|
30-04-2024
|
|
|
|
| RPG LIFE SCIENCES LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 30-Apr-2024 for Dividend |
|
|
|
|
|
30-04-2024
|
|
|
|
| Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2024. Kindly take the above on record. |
|
|
|
|
|
|
|
|
|
|
|
|
|